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Abstract
Thymosin β4 (Tβ4), a small G-actin sequestering peptide, mediates cell proliferation, migration, and angiogenesis.
Whether embryonic stem (ES) cells, overexpressing Tβ4, readily differentiate into cardiac myocytes in vitro and in
vivo and enhance cardioprotection following transplantation post myocardial infarction (MI) remains unknown.
Accordingly, we established stable mouse ES cell lines, RFP-ESCs and Tβ4-ESCs, expressing RFP and an RFP-
Tβ4 fusion protein, respectively. In vitro, the number of spontaneously beating embryoid bodies (EBs) was
significantly increased in Tβ4-ESCs at day 9, 12 and 15, compared with RFP-ESCs. Enhanced expression of cardiac
transcriptional factors GATA-4, Mef2c and Txb6 in Tβ4-EBs, as confirmed with real time-PCR analysis, was
accompanied by the increased number of EB areas stained positive for sarcomeric α-actin in Tβ4-EBs, compared
with the RFP control, suggesting a significant increase in functional cardiac myocytes. Furthermore, we transplanted
Tβ4-ESCs into the infarcted mouse heart and performed morphological and functional analysis 2 weeks after MI.
There was a significant increase in newly formed cardiac myocytes associated with the Notch pathway, a decrease in
apoptotic nuclei mediated by an increase in Akt and a decrease in levels of PTEN. Cardiac fibrosis was significantly
reduced, and left ventricular function was significantly augmented in the Tβ4-ESC transplanted group, compared with
controls. It is concluded that genetically modified Tβ4-ESCs, potentiates their ability to turn into cardiac myocytes in
vitro as well as in vivo. Moreover, we also demonstrate that there was a significant decrease in both cardiac
apoptosis and fibrosis, thus improving cardiac function in the infarcted heart.
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Introduction
Embryonic stem (ES) cells, derived from early embryos,
have the potential to self-renew and differentiate into any cell
type of all three primary germ layers: ectoderm, endoderm, and
mesoderm [1,2]. Previous studies have demonstrated that ES
cells can differentiate into a variety of specialized cell types
including cardiac myocytes both in vitro and in vivo [3-5].
However, the number of ES cell derived cardiac myocytes is
very limited in the absence of cell culture or genetic
modifications. Discovery of human ES cells and their potential
to differentiate into cardiac myocytes has provided a foundation
for future explorations to identify various growth factors and
signaling molecules that enhance cardiac myocyte
differentiation. Recent stem cell therapy studies suggest that
ES cells may provide a new approach to repair injured
myocardium. Indeed, transplanted ES cells in the infarcted
mouse and rat hearts can differentiate into cardiac myocytes,
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contributing to improved cardiac function [6-8]. However, data
obtained from these studies raise major concerns regarding the
limited capacity of cardiac myocyte differentiation following ES
cell transplantation. In this regard, identification of appropriate
factors, which will enhance cardiac myocyte differentiation from
ES cells, has gained recent significant attention. In fact, various
factors such as TGFβ2 [9], BMP4 [10], vitamin C [11], etc. have
been reported to promote cardiac myocyte differentiation from
ES cells. Nevertheless, there has been increased interest in
search of novel cardiomyogenic factors.
Thymosin β4 (Tβ4), a highly conserved, 43-amino acid
peptide, is the most abundant member of the β–thymosin
family in a majority of mammalian tissues [12-14]. Tβ4 has
been shown to play an important role in the regulation of cell
proliferation, migration, and angiogenesis [15-17]. Recently,
Tβ4 has been found to protect against myocardial injury via
inhibiting apoptosis and reducing infarct size with improved
myocardial function [15,16,18,19]. Moreover, knockdown of
Tβ4 by shRNA deprives embryonic endothelial progenitor cells
of their capacity to preserve myocardial function in the ischemic
heart [20]. In contrast, Tβ4 overexpression in endothelial cells
inhibits apoptosis after hypoxia-reoxygenation and also
decreases the adhesion of inflammatory cells to an endothelial
cell layer in vitro [20]. Furthermore, Tβ4 stimulates the
migration of hair follicle stem cells, resulting in hair growth [21],
and promotes differentiation of epicardial progenitor cells to
vascular cells [16]. However, there is no information available
regarding the role of Tβ4 in cardiac myocyte differentiation from
ES cells. In the present study, we examined the effects of Tβ4
on cardiac myocyte differentiation using a genetically modified
ES cell line (Tβ4-ESCs) and further investigated whether or not
Tβ4-ESCs transplanted in the mouse heart produce
cardioprotective effects following myocardial infarction.
Materials and Methods
Cell Culture
Undifferentiated mouse ES cells were cultured in the
absence of feeder cells on 0.1% gelatin coated plates in growth
medium consisting of DMEM supplemented with 0.2 mM L-
glutamine, 0.1 mM β-mercaptoethanol, 0.1 mM nonessential
amino acids, 10% fetal bovine serum (FBS), leukemia inhibitory
factor (LIF, 2000U/ml), 50U/ml penicillin, and 50 µg/ml
streptomycin, as we reported previously [9].
Construction of Expression Vectors
The mammalian expression vector (pTurboFP635-C)
encoding red fluorescent protein (RFP) was purchased from
Evrogen (Moscow, Russia). Mouse Tβ4 gene was generated
by PCR using high fidelity DNA polymerase and the primers
containing Bgl II and BamH I sites (forward: 5’-
AGATCTAAAGTCCAAGGCATGCTCC-3’ and reverse: 5’-
GGATCCTTACGATTCGCCA GCTTG-3’). The PCR product
was cloned to the vector pTurboFP635 along with the antibiotic
blasticidin resistance gene (Invitrogen Life Technologies,
Carlsbad, CA). Restriction enzyme digestion and DNA
sequencing was used to confirm the sequence of the mouse
Tβ4 gene.
Transfection and Generation of Stable Cell Lines
ES cells were cultured in 6-well plates at a density of 20,000
cells per well. Cells were transfected with or without Tβ4
expressing vectors using the lipofectamine 2000 (Invitrogen
Life Technologies) according to the manufacturer’s instructions.
Stably transfected cells were selected using the antibiotic
blasticidin. Cells were selected with 2 µg/ml blasticidin for 3
weeks and were monitored daily by fluorescence microscopy.
Transfected cells containing blasticidin resistance gene were
unaffected, whereas untransfected cells were killed during drug
selection. Surviving transfected cell clones expressing RFP
were identified by fluorescent microscopy. Following
identification of stably transfected ES cells, Tβ4 expressing ES
cells were maintained in a routine cell culture and used for
future studies.
Differentiation of ES Cells into Cardiac Myocytes
ES cells with or without Tβ4 overexpression were used for
cardiac myocyte differentiation. Differentiation of ES cells was
initiated using the hanging drop method, as described
previously [22]. In brief, hanging drops (~500 cells in 30 µl of
differentiation medium) were generated to form embryoid
bodies (EBs). The differentiation medium consisted of DMEM
supplemented with 0.2 mM glutamine, 0.1mM β-
mercaptoethanol, 0.1 mM nonessential amino acids and 15%
FBS, but without LIF. At day 3 (D3), the EBs were transferred
to 100 mm Petri dishes for 2 days. At D5, the EBs were plated
on 0.1% gelatinized plates (~30-40 EBs per 100 mm dish, ~2
EBs on a 12-well plates) and observed for beating EBs. The
medium was changed every 2 days. The morphological
changes and spontaneously beating areas in the differentiating
EBs were examined by light and fluorescent microscopy at D9,
D12 and D15.
Western Blot Analysis
EBs were washed with phosphate-buffered saline (PBS) and
lysed in RIPA buffer containing 150 mM NaCl, 10 mM Tris-HCl
(pH 7.4), 1 mM EDTA, 1% Triton X-100, 1% deoxycholic acid,
1 mM PMSF, and 10 mg/ml each of leupeptin and aprotinin.
The whole cell lysates (20-50 µg of protein) from each sample
were separated by electrophoresis on a 10% polyacrylamide
gel. The size-fractionated proteins were transferred to PVDF
membranes and blocked with a buffer containing 5% non-fat
milk and 0.1% Tween-20 in PBS for 2 hours. Goat anti-Tβ4 and
mouse anti-sarcomeric α-actin antibodies were diluted
(1:1,000) in blocking buffer, and membranes were incubated
with antibodies at 4°C for 24 hours. After incubation, the
membranes were washed 3 times with Tris-Buffered Saline
with Tween-20 (TBST) containing 10 mM NaCl, 10 mM Tris-
HCl and 0.1% Tween-20, followed by incubation with
horseradish peroxidase-conjugated anti-goat and anti-mouse
secondary antibodies at room temperature for 1 hour. The
membranes were washed with TBST buffer. The immune
complexes were developed by enhanced chemiluminescence
and visualized after exposure to Kodak x-ray film.
Thymosin β4 Expressing ES Cells Protect Hearts
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Real-Time PCR
Total RNA was extracted from ES cells with Tri-reagents
(Sigma), and samples were treated with DNase I (Ambion) to
prevent DNA contamination. cDNA was synthesized from 1 µg
total RNA using Superscript II reverse transcriptase and
random primers (Bio-Rad). Real-time PCR was performed
using a Bio-Rad I-cycler and master SYBR green I dye mix
(Bio-Rad). The following cycling conditions were used: 95°C for
5 min followed by 35 cycles of amplification (95°C denature for
15 seconds and 60°C for combined annealing/extension for 60
seconds). PCR primers were synthesized as follows: GATA-4
forward 5’- GGTTCC CAG GCCTCT TGC AAT GCG G -3’ and
reverse 5- AGT GGC ATT GCT GGA GTT ACC GCT G -3,
Mef2c forward 5’- AGATAC CCA CAA CAC ACC ACG CGC C
and reverse 5’- ATC CTT CAG AGA GTC GCATGC GCT T -3’,
Tbx6 forward 5’- AGC CAC CCA ACT ATG CAG CCA ACA C
-3 and reverse 5’ - GCATCC CGCTCC CTC TTA CAGTTT C
-3’, and β-tubulin forward 5’-
CCGGACAGTGTGGCAACCAGATCGG-3’ and reverse 5’-
TGGCCAAAAGGACCTGAGC GAACGG -3’. All reactions were
performed in duplicate. The level of cardiac gene expression
was normalized to the expression level of the housekeeping
gene tubulin.
Immunocytochemistry and Immunohistochemistry
EBs or digested EBs with Cellutron enzyme solution
(Cellutron Life Technologies) were washed with PBS and fixed
with 4% paraformaldehyde for 15 minutes at room temperature.
Non-specific blocking was performed by incubation for 1 hour
with blocking buffer containing 2% BSA, 0.1% Triton X100 in
PBS. After incubation, three washings were given with PBS.
Next, EBs were incubated with primary antibodies such as anti-
mouse sarcomeric α-actin (S-Actin, Sigma) and anti-Tβ4 at 4
°C for 24 hours. EBs were washed and then incubated with
fluorescein-conjugated anti-mouse secondary antibodies
(Vector Labs, CA) for 1 hour at room temperature. EBs were
mounted with Vectashield medium containing 4'-6-diamidino-2-
phenylindole (DAPI, Vector Labs, Burlingame, CA) to visualize
nuclei. Stained cells were analyzed by fluorescence (Olympus)
or confocal microscopy. For immunohistochemical staining,
heart tissues were fixed in 4% buffered formalin, embedded in
paraffin, and cut into 5 µm serial sections. The heart sections
were then deparaffinized, rehydrated, and stained with
Masson’s trichrome for visualization of interstitial fibrosis.
Interstitial fibrotic areas (with collagen stained blue) were
measured within the infarct, peri-infarct and non-infarct regions
and calculated using ImageJ software (NIH).
Determination of MMP-9 Activity
MMP-9 activity was examined in control and experimental
groups by using a commercially available mouse MMP-9 kit
(R&D Systems, Minneapolis, MN). Isolated heart tissue was
homogenized and supernatant was used to perform MMP-9
assay as per instructions in the kit. The developed reaction was
read at 450 nm using a BioRad plate reader. The examined
optical density was normalized to the previously determined
protein concentration in the samples and data was plotted as
A.U.
Mouse MI Model and Cell Transplantation
All animals were maintained and used as approved by the
University of Central Florida animal review board. MI was
performed in C57BL/6 mice (Jackson laboratories) by
permanent ligation of left coronary artery as described
previously [23-25]. In brief, mice were divided into four
experimental groups: Sham, MI, MI + RFP-ES cells and MI +
Tβ4 -ES cells. Mice were anesthetized with 2.5% isoflurane,
intubated, and ventilated using a rodent MiniVent (Harvard
Apparatus). A left thoracotomy was performed and the left
anterior descending (LAD) coronary artery was ligated with a
7-0 ligature (CP Medical). Following ligation, 2 intramyocardial
injections into the peri-infarct region were given containing total
5x104 cells in 20 µl media. Sham mice received the same
surgical procedures except the LAD ligation. Functional and
histological evaluations were performed 2 weeks after MI.
Animals were anesthetized with 2% inhalant isoflurane and
echocardiography was performed. After functional evaluation,
mice were sacrificed with an overdose of pentobarbital (100
mg/kg) followed by cervical dislocation. Hearts were removed,
transversely cut, and fixed in a formalin solution for preparation
of heart sections. In addition, heart homogenates were
prepared for western blot analysis and ELISA.
Detection of ES Cell-Derived Cardiac Myocytes In Vivo
Tissue sections were deparaffinized and used for double
immunolabeling to detect donor cells and cardiac myocytes. In
brief, sections were incubated with Rabbit polyclonal anti-RFP
antibody (1:500, Evrogen) to detect donor cells. After washing,
the sections were incubated with goat anti-rabbit antibody
(Invitrogen). Sections were then incubated with mouse anti-
sarcomeric α-actin antibody (1:40, Sigma) for cardiac
myocytes, and then sections were incubated with anti-mouse
antibodies (M.O.M. kit, Vector Laboratories). Negative controls
were used in each case by omitting primary or secondary
antibody. Sections were mounted with Anti-fade Vectashield
mounting medium containing 4,6-diamidino-2-phenylindole
(DAPI; Vector Laboratories) to stain nuclei and examined with
a Leica TCS SP2 laser scanning confocal microscope. For
Notch-1 staining, sections were incubated with Notch-1 mouse
monoclonal antibody (1:40, Abcam) using the M.O.M. kit
(Vector Laboratories) in a humidified chamber.
TUNEL Staining
Heart sections were deparaffinized and treated with
proteinase K (25 µg/ml in 100 mM Tris-HCl). Cardiac myocyte
apoptosis was detected using an in situ apoptotic cell death
detection kit (Roche Applied Biosystems) and for nuclear
visualization heart sections were also counterstained with 4',6-
diamidino-2-phenylindole (DAPI; Vector Laboratories). Sections
from each experimental group were examined by Olympus
fluorescence microscopy. The percentage of total apoptotic
nuclei was determined in the infarct and peri-infarct regions.
Caspase-3 Activity Assay
Caspase-3 activity assay was performed using a caspase-3
colorimetric activity assay kit (cat #K106-200, BioVision)
Thymosin β4 Expressing ES Cells Protect Hearts
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following the manufacturer’s instructions. Heart tissues were
homogenized in a RIPA buffer containing protease inhibitor
cocktail (Sigma) and then centrifuged at 14,000 x g for 5 min.
Supernatant was collected and then transferred into new
microfuge tubes. Protein assay was conducted using a Bio-Rad
assay dye and colorimetric reaction for caspase-3 activity was
measured at 405 nm in a Bio-Rad microtiter plate reader.
Capsase-3 activity is represented as arbitrary units (A.U.).
ELISA for pAkt and p-PTEN
The pAkt and p-PTEN activities were assayed using
Phospho-Akt (PAN) ELISA kit (X1844k, Exalpha Biologicals)
and Phospho-PTEN Sandwich ELISA kit (#7285, Cell
Signaling), respectively, following the manufacturer’s
instructions. In brief, heart samples were prepared and protein
concentrations were quantified as described above.
Standardized amount of samples were loaded to the wells
(already coated with antibody) provided in the kit and incubated
with detector antibody, HRP conjugate, substrate, and a stop
solution with subsequent washings after each step. The color
reaction was measured at 405 nm for pAkt activity and at 450
nm for p-PTEN activity in a Bio-Rad microplate reader. The
optical density for each sample was normalized to the total
proteins of each sample as determined by the Bradford assay.
Echocardiography
Two weeks after MI, mouse heart function was evaluated by
transthoracic echocardiography. Animals were anesthetized
with 2% inhalant isoflurane using a nose cone system and
echocardiography was performed using a Sonos 5500
Ultrasound system with a 15-6L hockey stick transducer. Left
ventricular internal dimension-diastole (LVIDd), left ventricular
internal dimension-systole (LVIDs), left ventricular volume at
end diastole (EDV), left ventricular volume at end systole (ESV)
were assessed in short axis view at the mid-papillary muscle
level. Fractional shortening [FS = (LVIDd-LVIDs)/LVIDd x 100]
and ejection fraction [EF = (EDV-ESV)/EDV x 100] were
calculated for each experimental group.
Statistical Analysis
Data are expressed as mean ± SE. Statistical analyses were
performed using an unpaired t test and one-way ANOVA
followed by Tukey test. A p value of <0.05 was considered
significant.
Results
Genetic Modification of Mouse ES Cells with the Tβ4
Gene
To examine the potential role of Tβ4 in the differentiation of
ES cells into cardiac myocytes, we generated a stably
transfected ES cell line overexpressing Tβ4. In Figure 1A, the
top panel shows pRFP-BL, a control vector constructed to
express RFP, whereas the bottom panel shows the expression
construct of Tβ4 gene, pRFP-Tβ4-BL. Mouse ES cells were
transfected with or without Tβ4 overexpressing vectors and
cells were selected with 2 µg/ml of blasticidin. After 4 weeks of
drug selection, two stable cell lines, RFP-ES cells, as a control,
and Tβ4-ES cells were obtained (Figure 1B). In order to
determine whether stably transfected Tβ4-ES cells have
increased expression of Tβ4, western blot analysis was
performed. Our data indicated a dramatic increase in the level
of Tβ4 expression in Tβ4-ES cells, compared with the RFP-ES
cells as a control (Figure 1C). Furthermore, we used
immunocytochemistry and confocal microscopy to confirm the
increased expression of Tβ4 in the Tβ4-ESCs (Figure 1D).
Enhanced Differentiation In vitro of Tβ4-ES Cells into
Cardiac Myocytes
To examine whether Tβ4 overexpression in ES cells has an
effect on cardiac myocyte differentiation in the cell culture
system, we generated EBs using the hanging drop method and
examined morphological changes up to D15. There was no
morphological difference observed between the EBs derived
from RFP or Tβ4-ES cells up to D5. The spontaneously beating
EBs were evident at D9 and were positively stained with
sarcomeric α-actin (S-Actin), a cardiac myocyte specific
marker, suggesting the presence of functional cardiac
myocytes. Interestingly, we observed a markedly increased
number of SA-positive areas in Tβ4 EBs, compared with the
control RFP-EBs (Figure 2A). Moreover, the differentiating Tβ4-
ES cells in the beating areas displayed a strong SA expression,
as shown in the bottom panel of Figure 2A. Figure 2B shows a
significant (p<0.05) increase in the number of beating EBs
compared with RFP controls at D9; 30.8% vs. 4.4%; D12;
48.3% vs. 7.8%, and at D15; 44.2% vs. 12.2%. We also
performed real-time PCR analysis to determine the expression
levels of cardiac specific transcriptional factors such as
GATA-4, Mef2c and Tbx6. The expression levels of GATA-4
were increased by 3 fold, Mef2c by 8 fold, and Tbx6 by 5 fold in
Tβ4 EBs, compared with the RFP control (Figure 2C).
We further examined whether or not Tβ4-ES-derived cardiac
myocytes are positive for additional cardiac specific markers,
such as S-actin. Figure 3A shows S-actin positive cells, which
display green fluorescence whereas DAPI shows blue nuclei. A
merged image of DAPI and S-actin, shown at high
magnification, demonstrates the z-line staining cardiac
myocyte-specific structural pattern (Figure 3A). We used
western blot analysis to quantify the protein expression of
cardiac specific S-Actin in beating EBs generated with or
without Tβ4-ES cells (Figure 3B). The expression level of S-
Actin was significantly (p<0.05) increased in Tβ4-EBs
compared with control as determined by densitometry
quantitative analysis (Figure 3C).
Enhanced Cardiac Myocyte Differentiation in the
Infarcted Heart following Transplantation of Tβ4-ES
Cells
In our cell culture system, we demonstrated that Tβ4
promoted cardiomyogenesis, as evidenced by
immunofluorescent staining, western blot and real-time PCR for
cardiac myocyte markers. Therefore, we hypothesized that
transplantation of genetically modified Tβ4-ES cells into the
heart would enhance cardiac myocyte differentiation in vivo.
Accordingly, we performed double immunolabeling to detect
Thymosin β4 Expressing ES Cells Protect Hearts
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donor ES cell-derived cardiac myocytes, using an anti-RFP
antibody for donor cells and an anti-sarcomeric α-actin
antibody for cardiac myocytes. As shown in Figure 4A, there
were both RFP-positive and S-actin positive cells in the
infarcted hearts transplanted with RFP-ES or Tβ4-ES cells,
whereas there were no RFP-positive cells in the sham and MI
groups. Interestingly, quantitative analysis further revealed that
the number of ES cells-derived cardiac myocytes was
significantly increased in the Tβ4-ES-transplanted heart
following MI, compared with the RFP-ES-transplanted control,
suggesting that transplanted Tβ4-ESCs enhance cardiac
myocyte differentiation in the infarcted heart in vivo (Figure 4B).
Notch Signaling Pathway Involving Cardiac Myocyte
Differentiation
In Figure 4C images demonstrate S-actin in red (a), RFP-
positive donor cells in green (b), Notch1-positive cells in purple
(c), nuclei in blue (d), merged images (e), and high
magnification of merged images (f). Our data suggests there is
a significant increase in Notch-1 expression in newly
differentiated cells in the hearts transplanted with RFP-ESCs
and Tβ4-ESCs relative to the MI control (Figure 4D).
Inhibition of Cardiac Myocyte Apoptosis in the Tβ4-ES
Transplanted Hearts following MI
The effects of transplanted Tβ4-ES cells on cardiac myocyte
apoptosis after MI were examined. Figure 5A shows the
representative photomicrographs of TUNEL positive nuclei per
heart section for both control and experimental groups.
Quantitative analysis revealed a significant increase in
apoptotic nuclei in the infarcted hearts relative to sham,
whereas the number of apoptotic nuclei was markedly reduced
in hearts transplanted with RFP-ESCs and Tβ4-ESCs
compared to MI (Figure 5B). Notably, hearts transplanted with
Tβ4-ESCs had a significantly lower number of apoptotic nuclei
than the hearts injected with RFP-ES cells (Figure 5B),
indicating that Tβ4 is a potential pro-survival factor that inhibits
the MI-induced cardiac myocyte apoptosis. Furthermore, there
was a significant decrease in caspase-3 activity in hearts
transplanted with either Tβ4-ES cells or RFP-ES cells,
compared to the infarcted hearts without cell transplantation
Figure 1.  Expression Vector and Confirmation of Tβ4 Expression.  A. Schematic drawing of the expression vectors, pRFP-BL
and pRFP-Tβ4 –BL, for generation of stable ES cell lines. The cDNA coding for mouse Tβ4 was generated by PCR and cloned to
the C-terminal of RFP gene in the same open reading frame. B. Fluorescent microscopy of red fluorescent protein expression in
undifferentiated stable RFP-ES cells (b) and Tβ4-ES cells (d). Scale = 100µm. C. Western blot of mouse Tβ4 protein. D.
Representative photomicrographs of Tβ4 expression in RFP-ES cells (top panels) and Tβ4-ES cells (bottom panels). RFP is shown
in red, Tβ4 in green, nuclei in blue and merged images shown in far right panels. Scale = 200µm.
doi: 10.1371/journal.pone.0075580.g001
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(p<0.05, Figure 6A). However, there was no statistical
significance in caspase-3 activity between Tβ4-ES cell and
RFP-ES cell groups.
Multiple signaling pathways contribute to apoptotic inhibition,
including the well-known PI3K/Akt survival pathway. To
examine whether inhibition of PTEN, a negative regulator of the
Akt pathway, is implicated in cardioprotection of Tβ4-ES cells
against MI, we performed ELISA for phospho-PTEN. It was
found that hearts transplanted with either Tβ4-ES cells or RFP-
ES cells had a significant reduction in PTEN expression
compared with the MI group, but there was no significant
difference between the cell-transplanted heart groups (Figure
6B). Additionally, our quantitative analysis suggests Akt
expression was significantly augmented following
transplantation of RFP-ESCs and Tβ4-ESCs post-MI relative to
MI controls (Figure 6C).
Reduced Cardiac Fibrosis in the Tβ4-ESC Transplanted
Hearts following MI
To examine the effects of transplanted Tβ4 on interstitial
fibrosis, we stained heart sections with Masson’s trichrome
(Figure 7A) and quantitated the collagen-positive fibrotic areas
using NIH ImageJ software. Quantitative data analysis
demonstrated that both transplanted Tβ4-ES and RFP-ES cells
significantly reduced the amount of fibrosis in the infarcted
hearts at day 14 after MI (Figure 7B). Importantly, hearts
transplanted with Tβ4-ESCs had a further significant reduction
in cardiac fibrosis, compared with the RFP-ESC group (p<0.05,
Figure 7B), suggesting that genetic modification of ES cells
with Tβ4 is a novel therapeutic strategy to attenuate cardiac
remodeling following MI.
To elucidate mechanisms by which RFP-ES and Tβ4-ES
cells inhibit fibrosis post-MI, levels of MMP-9, a pro-fibrotic
modulator, were examined. Our data suggested a significant
reduction in MMP-9 expression following MI in RFP-ES and
Tβ4-ES cell transplanted hearts compared to MI hearts (Figure
Figure 2.  Effect of Tβ4 Expression on ES Cell Differentiation.  A. Fluorescent microscopy of EBs derived from RFP-ES and
Tβ4-ES cells. At D12 EBs were stained with anti- sarcomeric α-actin (S-actin) (green) and counterstained with DAPI for nuclear
visualization (blue). The lower panel shows S-actin staining in a beating area (square box) in the EBs derived from Tβ4-ES cells.
Scale = 200µm. B. Percentage of beating EBs during cardiac myocyte differentiation. Spontaneously beating EBs were examined
and counted under a light microscope at D9, 12 and 15. C. Real-time PCR analysis of gene expression of GATA-4, Mef2c and Tbx6
at D12. Data are represented as mean ± SEM, *p< 0.05; vs. RFP ESCs.
doi: 10.1371/journal.pone.0075580.g002
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7C). However, statistical significance was not obtained
between RFP-ESC and Tβ4-ESC groups (Figure 7C).
Improved Cardiac Function in the Infarcted Hearts
following Transplantation of Tβ4-ES Cells
We performed echocardiography to evaluate the effects of
transplanted Tβ4-ES cells on cardiac function 2 weeks after MI.
As shown in Figure 8, there was a significant (p<0.05)
decrease in both fractional shortening and ejection fraction in
the infarcted mouse hearts. Transplanted ES cells expressing
RFP significantly improve cardiac function following MI (Figure
8D). Interestingly, transplanted Tβ4-ES cells further increased
fractional shortening in the infarcted hearts, compared with the
RFP-ES cells (Mean ± SEM, Tβ4-ESCs: 43.81±1.51 vs. RFP-
ESCs: 38.35±1.75, p<0.05, Figure 8D) and ejection fraction
(Mean ± SEM, Tβ4-ESCs: 77.17±1.56 vs. RFP-ESCs:
70.61±2.70, p<0.05, Figure 8G), suggesting that genetic
modification of ES cells with Tβ4 produces more beneficial
effects on cardiac function following MI.
Discussion
Stem cell therapy is emerging as a novel therapeutic
approach to treat various heart diseases including myocardial
infarction. Increasing evidence from embryonic and adult stem
cell transplantation studies demonstrate that transplanted stem
cells significantly improve cardiac function, which is likely
associated with the inhibition of cardiac apoptosis and fibrosis
and generation of new cardiac myocytes [23,26-28]. However,
the amount of differentiated cardiac myocytes following
transplantation is very limited. Identification of new approaches
to enhance cardiac myocyte differentiation from ES cells would
bring researchers a step closer to optimizing cell therapy for
clinical applications. To date, several strategies for inducing
differentiation of stem cells into cardiac myocytes have been
reported including the use of dimethysulfoxide [23],
transforming growth factor-β [9], ascorbic acid [11], retinoic
acid [29], 5-Aza-2’deoxycytidine [30], and bone morphogenic
protein-2 [22].
Tβ4, a small acidic actin-sequestering peptide, participates in
many important cellular events including inhibition of apoptosis
and angiogenesis in the heart [15-18]. It has been suggested
that Tβ4 is a novel signaling molecule, which activates various
cell type differentiation [15,16,21,31]. However, its role in the
differentiation of ES or adult stem cells into cardiac myocytes
has not been examined. Therefore, we designed the present
study to determine whether overexpression of Tβ4 in ES cells
would enhance cardiac myocyte differentiation in the cell
culture system and in vivo. To the best of our knowledge, this is
the first report on the evaluation of the effects of Tβ4 on cardiac
myocyte differentiation from genetically modified ES cells.
Figure 3.  Tβ4-ES Cells Differentiate into Cardiac Myocytes.  A. Confocal fluorescent microscopy of S-actin expression in Tβ4
EB-derived cardiac myocytes. Cells were stained with an anti-S-actin (a, green) and the nuclei in the same field were counterstained
with DAPI (b, blue). Panel c shows the merged image for the overlay of S-actin and the nuclei. Panel d displays the image acquired
at higher magnification (D, 400X). Scale = 25µm. B. Western blotting of S-actin expression in RFP-ESCs and Tβ4-ESCs. C.
Quantitative analysis of S-actin expression. Data are represented as mean ± SEM, *p< 0.05; vs. RFP-ESCs.
doi: 10.1371/journal.pone.0075580.g003
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In the present study, we established two stably transfected
cell lines, RFP-ES and Tβ4-ES cells, and observed no effect on
cell proliferation, nor significant changes in morphology in the
EBs, compared with untransfected ES cells (data not shown).
We observed beating EBs derived from stably transfected
RFP-ES cells at D9 and this was further enhanced at D12 and
D15. Our data is in accordance with earlier published studies
suggesting that cardiac myocyte beating generally occurs after
D7 [10,32-34]. Interestingly, Tβ4-ES cells had a significant
increase in the number of beating EBs, compared with RFP-ES
cells. We further confirmed the presence of cardiac myocytes
in the beating EBs using immunofluorescent staining as well as
western blot data for S-actin. Similarly, It has been reported
that Tβ4 plays a significant role in the heart development at
embryonic stage (E10) and at E14.5 because expression of
Tβ4 was widely observed in the heart [16]. Our cell culture data
demonstrating increased beating cardiac myocytes derived
from Tβ4-EBs at D9 is in the agreement of the role played by
Tβ4 in the developing heart. Furthermore, our real time PCR
data from Tβ4 derived EBs revealed significant up regulation of
mRNA levels of cardiac transcription factors, GATA-4, Mef2c
and Tbx6, suggesting a possible role of up regulating these
early transcriptional factors in cardiac myocyte differentiation
which is in accordance with previous data [35-37].
Based on our cell culture studies we hypothesized that
transplanted Tβ4-ESCs would promote cardiac myocyte
differentiation and provide indigenous cardioprotection, thus
protecting left ventricular function in the post-MI heart. Our data
suggests that Tβ4-ESCs generate significant numbers of new
cardiac myocytes in the injured heart compared to all other
experimental and control groups (Figure 4B). Similarly,
pretreatment of mice with Tβ4 peptide promoted cardiac repair,
which was attributed to the differentiation of epicardial cells into
cardiac myocytes [16]. However, the administration of Tβ4 after
MI did not reprogram epicardial cells into cardiac myocytes
[16]. Moreover, the native Tβ4 peptide has been the subject of
a clinical trial for the treatment of MI [38]. The current study did
not investigate the effects of Tβ4-ES cells on epicardial cell
Figure 4.  Effects of Tβ4 Expression on ES Cell Cardiac Myocyte Differentiation Post MI.  A. Representative
photomicrographs of immunostained tissue sections showing S-actin in red (a, e, i, m), RFP in green (b, f, j, n), dapi in blue (c, g, k,
o) and merged images in pink (d, h, l, p). Scale = 50µm. B. Quantitative analysis shows a significant increase in cardiac myocyte
differentiation in the Tβ4-ESC group. *p< vs. MI, #p<0.05 vs. RFP-ESCs. C. Representative photomicrographs showing S-actin in
red (a), RFP in green (b), Notch1 in purple (c), dapi in blue (d), merged images in pink (e), and at high resolution (f). Scale=100µm.
D. Histogram shows expression levels of Notch-1 in all groups. #p<0.05 vs. sham, *p<0.05 vs. MI, and $p<0.05 vs. RFP-ESCs.
doi: 10.1371/journal.pone.0075580.g004
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differentiation but suggest that genetically modified Tβ4-ESCs
may be more advantageous for cardiac myocyte regeneration
in the clinical setting as they can directly differentiate
themselves into cardiac myocytes.
The Notch pathway plays a pivotal role in a myriad of cardiac
developmental and pathological scenarios, including regulation
of cardiac progenitor cell fate and the proliferation of cardiac
myocytes [24,25,39]. In the present study, we demonstrate that
transplanted Tβ4-ESCs differentiate into cardiac myocytes and
these newly formed cells have increased expression of Notch-1
in the post-MI heart, suggesting Notch-1 is also regulated in the
derivation of cardiac myocytes from the transplanted cells.
However, previous studies have suggested transient activation
of Notch-1 following cardiac assault promotes myocardial
repair and regeneration [24]. Moreover, we acknowledge the
interrelationship of the Notch-1 pathway and other reparative
and protective pathways occur during myocardial injury, which
are complex and multifaceted. Identification of these
Figure 5.  Transplanted Tβ4-ES Cells Inhibit Cardiac Myocyte Apoptosis in the Infarcted Heart.  A. Representative
photomicrographs of total nuclei stained with DAPI in blue (a, d, g, j), apoptotic nuclei stained with TUNEL in red (b, e, h, k), and
merged nuclei in pink (c, f, i, l). Scale = 100µm. B. Quantitative analysis of apoptotic nuclei per tissue section. *p<0.01 vs. MI,
#p<0.05 vs. sham, and $p<0.05 vs. RFP-ESCs.
doi: 10.1371/journal.pone.0075580.g005
Figure 6.  Effects of Tβ4 Expression on Caspase-3, pAkt, and p-PTEN Activities.  Heart homogenates from each group were
prepared for ELISA analysis of caspase-3, Akt, and p-PTEN. A. Quantitative analysis of caspase-3, B. p-PTEN, and C. pAkt activity
in the hearts following cell transplantation. Data were represented as Mean ± SEM; *p<0.01 vs. MI, #p<0.05 vs. sham. n = 4-5
animals per group.
doi: 10.1371/journal.pone.0075580.g006
Thymosin β4 Expressing ES Cells Protect Hearts
PLOS ONE | www.plosone.org 9 September 2013 | Volume 8 | Issue 9 | e75580
associations between Notch-1 signaling molecules and Tβ4-
ESCs is well beyond the scope of the current study.
Additionally, we have examined whether transplanted Tβ4-
ES cells enhance cardiac repair through additional protective
mechanisms, including inhibition of cardiac myocyte apoptosis
following MI. It has been reported that Tβ4 reduces cardiac
myocyte death in the cell culture system after hypoxia [20] and
also in the adult mouse heart after MI, regardless of
intramyocardial or intraperitoneal systemic application [15].
Consistent with previous studies, we have found that
transplantation of unmodified ES cell reduces to some extent
cardiac myocyte apoptosis in the MI model [8,9]. In particular,
transplanted Tβ4-ES cells provided significantly greater
protection against cardiac myocyte apoptosis in the infarcted
heart than RFP-ES cells.
In an attempt to define mechanisms promoted by
transplanted Tβ4-ES cells, which govern apoptosis following
MI, we investigated the potential correlation between Tβ4-
ESCs and the Akt pathway. Widely accepted, the Akt signaling
pathway plays a pivotal role in a host of cellular processes
including growth, proliferation, and survival. Phosphatase and
tensin homolog (PTEN) inhibits PI3K phosphorylation and
subsequent phosphorylation and activation of Akt. Our data
suggests a significant increase in PTEN activity following MI,
which is corroborated in other myocardial injury studies [23,40].
However, following transplantation of either Tβ4-ES cells or
RFP-ES cells, we report a significant decrease in PTEN
expression, compared with the MI group. Based on these
findings, we hypothesized that downregulation of PTEN would
lead to increased Akt activity, which would account for the
diminished cardiac myocyte apoptosis and abrogated adverse
cardiac remodeling documented within the current study.
Therefore, our assessed levels of Akt by ELISA demonstrate
significant upregulation in Akt activity in hearts transplanted
with either Tβ4-ES cells or RFP-ES cells. In accordance with
our findings, a recent report has demonstrated that
administration of Tβ4 promotes cardiac myocyte survival
through activation of Akt in a mouse MI model [15]. Ultimately,
our data suggest that Tβ4-ES cells enhance cardioprotection
against MI at least in part through inhibition of apoptosis and
activation of the Akt pathway. Whether the enhanced
cardiomyogenesis observed in Tβ4-ES cell-transplanted hearts
is consequent to augmentations to PTEN/Akt pathway was not
addressed within the context of the current study and will
require future investigation.
Moreover, cardiac myocyte apoptosis and fibrosis formation
contribute significantly to the pathological cardiac remodeling
following MI [23]. A dramatic loss of cardiac myocytes in the
infarcted heart results in subsequent replacement and
proliferation of non-myocytes, such as cardiac fibroblasts,
forming a fibrotic network to rescue the architecture of injured
myocardium. This process involves metalloproteinase (MMP)
Figure 7.  Transplanted Tβ4-ES Cells Reduce Cardiac Fibrosis in the Infarcted Mouse Heart.  A. Representative
photomicrographs of tissue sections stained with Masson’s trichrome at D14 post MI surgery. Scale =100µm. B. Quantitative
analysis of interstitial fibrosis for control and experimental groups. #p<0.05 vs. sham, *p<0.05 vs. MI, and $p<0.05 vs. RFP-ESCs.
C. Histogram illustrates quantitative MMP-9 expression. #p<0.05 vs sham, *p<0.05 vs. MI. n = 5-7 animals per group.
doi: 10.1371/journal.pone.0075580.g007
Thymosin β4 Expressing ES Cells Protect Hearts
PLOS ONE | www.plosone.org 10 September 2013 | Volume 8 | Issue 9 | e75580
activation, extracellular matrix (ECM) degradation and collagen
deposition in the infarcted heart, leading to interstitial and
vascular fibrosis, scar formation, and eventual cardiac
dysfunction. In agreement to the previous studies [8],
transplanted ES cells (Tβ4-ES or RFP-ES cells) inhibit the
formation of fibrosis in the MI model. Furthermore, there is a
significant decrease in fibrosis in the infarcted heart
transplanted with Tβ4-ES cells, compared with the RFP-ES cell
group. Although the underlying mechanism remains to be
examined, our data clearly indicates that ES cells
overexpressing Tβ4 can produce anti-fibrotic effects mediated
through MMP-9 inactivation following MI.
Finally, we examined the effects perpetrated by our Tβ4-
ESCs on cardiac function following MI. For the first time, we
have found that transplanted ES cells overexpressing Tβ4
significantly improve cardiac function 2 weeks after MI, as
demonstrated by increased fractional shortening and ejection
fraction. We suggest that enhanced left ventricular output
following transplantation of Tβ4-ESCs is indicative of enhanced
cardiac myocyte differentiation and augmented
cardioprotection provided by these cells in the injured
myocardium.
In summary, we have examined the effects of Tβ4 on cardiac
myocyte differentiation and cardioprotection using genetically
modified ES cells. Our data collectively suggests 1) Tβ4
overexpression enhances differentiation of mouse ES cells into
functional cardiac myocytes in vitro and in vivo, 2) Tβ4-ESCs
inhibit apoptosis through down-regulation of PTEN and
upregulation of Akt in the infarcted myocardium, 3)
transplantation of Tβ4-ESCs reduce fibrosis formation via
inhibition of MMP-9 activation following MI, and 4) enhanced
left ventricular function is obtained following transplantation of
Tβ4-ESCs post-MI. It is suggested that transplantation of
genetically modified Tβ4-ES cells into the injured heart is a
novel therapeutic approach, which provides additional
differentiation potential and enhanced cardioprotection against
MI, relative to unmodified ES cells.
Figure 8.  Transplanted Tβ4-ES Cells Improve Cardiac Function in the Infarcted Heart.  Echocardiography was performed D14
following MI. A. Raw functional data. Histograms show average quantified measurements of B. left ventricular internal diameter
during diastole (LVIDd) C. left ventricular internal diameter during systole (LVIDs) D. fractional shortening FS% E. end diastolic
volume (EDV) F. end systolic volume (ESV) G. and ejection fraction EF% at 2 weeks after MI for all treatment groups. #p<0.05 vs.
sham, *p<0.05 vs. MI, and $p<0.05 vs. RFP-ESCs. Data set are from n=6-8 animals/group.
doi: 10.1371/journal.pone.0075580.g008
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